We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,082 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
31/10/2017 15:22 | Ess They are sensitive on the BT thread, lol. | montyhedge | |
31/10/2017 15:20 | Pfizer may make an opportunistic approach, outside chance only and Not a reason to buy the shares imv. They made an informal approach at near £19 reportedly, which was rebuffed. The FT covered the story at the time from memory. | essentialinvestor | |
31/10/2017 15:00 | Emma is very naive bring back Witty he knows how to deal with the city. | montyhedge | |
31/10/2017 15:00 | The CEO has at least 2-3 years, before there are any serious questions imv. Andrew had great presentation skills, even his detractors accepted that. | essentialinvestor | |
31/10/2017 15:00 | I’m in for a few more £’s worth, near 6% annual divi is silly but i’ll Park some more cash here GSK can take my (IMM) retirement shares out,next Spring for £40+ a share! | ny boy | |
31/10/2017 14:53 | Emma needs to announce something positive soon otherwise I think the Institutions will want her replaced...GSK has a reasonable product mix and there were some positives in the recent results, so her own presentation skills have obviously fallen short. In todays climate that is not acceptable, and must be addressed...she needs to do something to stop the rout and restore confidence. Sorry to sound so negative but I did prefer the skills of the previous CEO despite others having mixed opinions. | cyberian | |
31/10/2017 14:49 | GILD comments on their HIV franchise today a factor in the drop imv. | essentialinvestor | |
31/10/2017 14:42 | I think Youre a week ahead of yourself! - ex div on Friday 9th Nov payble 15th Dec | wi1l | |
31/10/2017 14:31 | Could not resist just stepped in at 1353.9p Ex Div on Friday 19p in the bag. | montyhedge | |
31/10/2017 10:19 | 31st oct TraderMichael buy tp 1950p unchanged | tradermichael | |
31/10/2017 09:52 | 31st oct Jefferies buy tp 1540p cut from 1700p | philanderer | |
30/10/2017 16:51 | NVS announced another oncology acquisition today for approximately $4 Billion. Hopefully they will be kind enough to exercise the put option at some point, 2019 would be my guess. | essentialinvestor | |
30/10/2017 16:38 | GSK do indeed have a medication for that, Lamotrigine. By no means am I inferring monty needs that!. | essentialinvestor | |
30/10/2017 15:11 | Monty,Calm down,and take your Medication.Your too excitable.Too Manic | garycook | |
30/10/2017 15:08 | Your short-changing yourself monty 1379 ATM. | essentialinvestor | |
30/10/2017 15:07 | WS always seems to be 20p higher on average...currently now at 1398p equiv. at £/$ 1.3180 exchange rate....hopefully can improve here over coming weeks, at least! | cyberian | |
30/10/2017 15:05 | When GSK were 1550p the other week, I had GSK on my wish list at 1425p. Now at 1369p I can't believe that opportunity arose. I'm still dreaming lol | montyhedge | |
30/10/2017 14:57 | Trader M Yes but the naive CEO opened her gob. | montyhedge | |
30/10/2017 14:55 | Better in this case is an understatement, which may be why it has preferred vaccine designation in the US. | essentialinvestor | |
30/10/2017 14:50 | Should have pushed the share price up to 1950p ..... | tradermichael | |
30/10/2017 14:44 | I paid £160 for its rival Shingles Vac, now I wish I waited for GSK its better. | montyhedge | |
30/10/2017 14:43 | Well, its two potential blockbuster drugs, a vaccine for Shingles and a three-in-one inhaler for the treatment of a severe respiratory illness, chronic obstructive pulmonary disease (COPD). | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions